American Academy of Dermatology Meeting

Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of Dermatology Annual Meeting.

In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting.

In this video, Raj Chovatiya, MD, PhD, discusses updates on oral therapies in psoriasis from the American Academy of Dermatology Annual Meeting.

ORLANDO — Dermatologists should take action to treat patients who present with cutaneous manifestations of metabolic disease, according to a speaker at the American Academy of Dermatology Annual Meeting.

ORLANDO — Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, according to a speaker at the American Academy of Dermatology Annual Meeting.

ORLANDO — Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse events, according to a speaker at the American Academy of Dermatology Annual Meeting.

ORLANDO — Treating acne in transmasculine patients requires sensitivity to unique challenges, according to a speaker at the American Academy of Dermatology annual meeting.

ORLANDO — A subset of patients treated with delgocitinib cream 20 mg/g for moderate to severe chronic hand eczema achieved a “super-response,” by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting.

ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting.

ORLANDO — Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab compared with placebo, according to a presenter at the American Academy of Dermatology Annual Meeting